Chuangyebang learned that recently, Huili Bio, a new generation of synthetic biology enzyme computing design platform, announced the completion of nearly 300 million yuan in Series A financing, jointly led by Legend Capital and Boyuan Capital, Qianji Capital, Yunqi Capital, Zhongwei Capital joined the investment, and Taihe Capital acted as the exclusive financial advisor. This round of financing will be used to accelerate the construction and operation of large-scale production facilities, the research and development of new product pipelines, and the expansion of talent teams.
Founded in 2018, Huili Bio is committed to the computational design of the core enzyme components of synthetic biological reactions. The cutting-edge research and development achievements have emerged one after another. It is one of the few bio-manufacturing companies with core technology, large-scale mass production, and commercial closed-loop comprehensive capabilities. It has been used in pharmaceutical intermediates. , animal health, food and other fields of landing solutions. The company has a R&D center in Tianjin and a production base in Taizhou, Jiangsu. At present, the base has started a flexible production line expansion project.
As a new-generation technological revolution industry, synthetic biology is both economical and valuable. According to McKinsey’s prediction, 70% of chemically manufactured products can be produced by biological means in the future. As the most core element that determines the efficiency of biosynthesis, the transformation of enzymes will greatly expand the reaction space. Huili Bio’s core technology platform, the enzyme computing design platform, is the first computing platform in China to realize the full-scene design of enzymes. It conducts a deeper analysis and mining design of the “sequence-structure-function” of enzymes, which is different from the previous generation. Directed evolution technology, the company uses computational design technology to greatly optimize the screening efficiency, efficiently realize the transformation of enzyme functions, and transformatively promote the development of green biomanufacturing.
At present, the company has transformed products in the pharmaceutical field based on this platform, and efficiently completed the development from laboratory, industrial production to commercialization. Compared with traditional chemical methods, the cost has been reduced by nearly 30%, and the yield has been increased by nearly 70%. More than 10 innovative products have been deployed.
The core team of Huili Biology graduated from the Institute of Microbiology, Chinese Academy of Sciences, University of Groningen, East China University of Science and Technology and other universities at home and abroad. Rich experience in technology, commercial selection, and scale-up production.
The company’s technical team is committed to computational design, enzyme engineering transformation, and synthetic design. On this basis, a series of chemical biosynthesis pathways have been constructed, including peptide drug enzymatic assembly, β-amino acid biosynthesis, and nitrogen heterocyclic drugs. A number of technologies such as sequential fermentation of intermediates have successfully achieved industrial application. Mr. Guo Hongming, the chairman of the company, is a 30-year veteran of the industry who has brought traditional biological manufacturing into the era of synthetic biology. He has a deep understanding of the large-scale production and commercialization of technology. In the past, he has realized the commercialization of many domestic first and world-leading products. .
In recent years, the synthetic biology track has become wider and wider. Prof. Wu Bian, an expert in the field, said: “In the field of synthetic biology technology, infinite possibilities can be unearthed, which increases the imagination space for the future development of human society. The organic combination has accelerated the arrival of this era. But to put it into practice, entrepreneurs and practitioners still need to focus on the market to make products, focus on transformation and technology, clarify their ideas, and keep their feet on the ground.”
Regarding this financing, Ji Haiquan, executive director of Legend Capital, said: “The market for synthetic biomaterials is broad, and it is an important field in the direction of green and low carbon. As the core component of synthetic biology, its design and transformation will provide more opportunities for traditional biotechnology industries. Bringing low-cost and sustainable green production methods. Legend Capital has long been concerned about the investment in the ‘IT+’ industry. Huili Bio is a model of the combination of information technology and biotechnology (IT+BT). The company’s team background combines production and research, with Differentiated product selection and multi-pipeline extension capabilities. The company has mastered the industry-leading enzyme computing design technology, and has quickly realized the large-scale production of high value-added products such as pharmaceutical intermediates through the layout of the entire industry chain, and has received full support from leading customers in the industry. Approved.”
Ma Jinbo, vice president of Boyuan Capital Investment, said: “The ESG concept has become a global consensus, and low-carbon, environmental protection, green and sustainable development will become the main direction of social progress, and also the focus and overall layout of Boyuan. The profound understanding of catalysis-related component mining, mechanism analysis, enzyme engineering transformation, and synthetic design, together with the original full-scene enzyme engineering computing design platform, and working with industry veterans with more than 30 years of practical experience in the biological/chemical industry make Huili in the selection. It has great advantages and characteristics in terms of products and costs. It is believed that Huili Bio will become an important leader in the process of realizing low-carbon transformation and sustainable development in the domestic chemical industry.”
Shen Xiaoyin, managing director of Qianji Capital, said: “With the maturity of basic technologies such as sequencing, gene editing, and protein structure prediction, we believe that the application of synthetic biology in the field of biomanufacturing is a long-term change trend in the future on a global scale. At the same time, Compared with Europe and the United States, China’s more mature large-scale fermentation industry also provides a good development soil for the implementation of synthetic biology technology. We are optimistic that Huili’s enzyme engineering computing design platform will greatly improve R&D efficiency, and the team’s ability to scale up production processes. With the accumulation of decades of experience, I believe that the company can promote the multi-faceted innovation of traditional production methods in the industry.”
Feng Yao, managing director of Yunqi Capital, said: “Synthetic biology is an important field for the development of the green economy and will become the next-generation technological revolution industry. We are very optimistic about Huili’s general computing capabilities based on rationally designed enzymes and proteins, and become a leading leader in the field of synthetic biology. A company with multi-pipeline product capabilities. On the one hand, the team’s underlying capabilities in enzyme protein design are at the domestic or even international leading level; The Huili team has made more cutting-edge progress in the field of synthetic biology, helping to upgrade the wisdom of the industrial chain.”
Xu Wei, partner of Zhongwei Capital, said: “Zhongwei Capital is optimistic about the opportunities in the synthetic biology industry for a long time, and enzymes are the key point of synthetic biology applications. The Huili team is a rare combination of ‘technology + industry’ in the industry. The team not only With the industry’s advanced enzyme engineering capabilities and decades of practical experience in the biochemical industry, the enzyme engineering computing platform built by Huili can greatly improve the efficiency of obtaining target enzymes, thereby realizing pipeline commercialization faster. The pipeline selection of the company has a unique and clear positioning, and the market competitive advantage is obvious. I look forward to the team’s continued growth and more surprises after the completion of this round of financing.”
Sun Si, director of Taihe Capital, said: “R&D efficiency is the core element for enterprises in the field to establish their advantages. The Huili Bio team has many years of successful experience in industrialization and has achieved a closed loop of ‘R&D-production-manufacturing’ on several products. Through this round of financing, the company will further expand its leading edge in R&D efficiency and mass production capacity, and realize the implementation and application of new products/new fields.”
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Investment Community Venture Bangtou China Network
Related events
- Huili Bio completed nearly 300 million yuan in Series A financing2022-07-04
- Yuce Bio completed nearly 100 million yuan in Series A financing2022-06-29
- Changjin Bio received 140 million yuan in Series A financing, led by Food Core Capital 2022-06-23
- Mojia Bio announced the completion of more than 80 million US dollars in Series B financing2022-06-23
- Synthetic biotechnology company “Yanwei Technology” received 50 million yuan in the first round of financing2022-06-06
This article is reprinted from: https://readhub.cn/topic/8hmT6Jz6SKd
This site is for inclusion only, and the copyright belongs to the original author.